Key facts
- It has raised $29.0M across 1 recorded rounds; the latest was Early Stage VC ($15.0M) in Sep 2024.
- Notable investors include 1315 Capital, East Seattle Partners, Harro Hofliger, Kineticos Life Sciences Management, Partners Edge (USA).
- Experic has filed 2 Form Ds with the SEC since 2024, most recently May 2025 ($15.0M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Experic
Funding rounds
1 roundsAbout Experic
Provider of contract manufacturing and pharmaceutical supply services intended to support every phase of a product's life cycle from clinical to commercial scale. The company's services include process development, analytical, clinical trial supply, vendor management, packaging, and logistics technology, enabling clients with a hands-on, personalized approach to their development projects.
- Sector
- Healthcare
- HQ
- Cranbury, NJ, United States
- Founded
- 2015
- Employees
- 54
- Website
- expericservices.com/
- Ownership
- Privately Held (backing)
Experic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Experic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Experic in its N-PORT filings yet. We sweep new filings monthly.